NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class (Descending) | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
42388-0025-46 | 42388-0025 | Cabozantinib | CABOMETYX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan. 9, 2023 | In Use | |
42388-0025-57 | 42388-0025 | Cabozantinib | CABOMETYX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan. 9, 2023 | In Use | |
50742-0366-30 | 50742-0366 | Gefitinib | Gefitinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | April 27, 2023 | In Use | |
51407-0760-12 | 51407-0760 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF | Oral | April 14, 2023 | In Use | |
63539-0927-01 | 63539-0927 | Lorlatinib | Lorbrena | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK/ROS1 | Oral | Jan. 3, 2023 | In Use | |
65597-0407-20 | 65597-0407 | Pexidartinib hydrochloride | Turalio | 125.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | CSF1R, KIT, FLT3 | Oral | Feb. 1, 2023 | In Use | |
65597-0407-28 | 65597-0407 | Pexidartinib hydrochloride | Turalio | 125.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | CSF1R, KIT, FLT3 | Oral | Feb. 1, 2023 | In Use | |
67184-0531-01 | 67184-0531 | Gefitinib | Gefitinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Feb. 13, 2023 | In Use | |
67184-0531-02 | 67184-0531 | Gefitinib | Gefitinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Feb. 13, 2023 | In Use | |
67184-0531-03 | 67184-0531 | Gefitinib | Gefitinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Feb. 13, 2023 | In Use | |
00003-0852-11 | 00003-0852 | Dasatinib | Sprycel | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | June 3, 2009 | Jan. 26, 2011 | In Use |
00003-0852-22 | 00003-0852 | Dasatinib | Sprycel | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 30, 2008 | In Use | |
00078-0670-66 | 00078-0670 | Pazopanib Hydrochloride | Votrient | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, Lck, FMS | Oral | July 12, 2016 | Oct. 31, 2024 | In Use |
00078-0698-02 | 00078-0698 | RYDAPT | Rydapt | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | April 28, 2017 | In Use | |
00078-0698-19 | 00078-0698 | RYDAPT | Rydapt | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | April 28, 2017 | In Use | |
00078-0698-51 | 00078-0698 | RYDAPT | Rydapt | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | April 28, 2017 | In Use | |
00078-0698-99 | 00078-0698 | RYDAPT | Rydapt | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | April 28, 2017 | In Use | |
00078-0709-56 | 00078-0709 | Capmatinib | TABRECTA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | MET | Oral | May 6, 2020 | In Use | |
00078-0709-94 | 00078-0709 | Capmatinib | TABRECTA | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | MET | Oral | May 6, 2020 | In Use | |
00078-0716-56 | 00078-0716 | Capmatinib | TABRECTA | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | MET | Oral | May 6, 2020 | In Use | |
00078-0716-94 | 00078-0716 | Capmatinib | TABRECTA | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | MET | Oral | May 6, 2020 | In Use | |
00597-0143-60 | 00597-0143 | Nintedanib | Ofev | 100.0 mg/1, 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGFR, PDGFR, FLT3, CSF1R | Oral | Oct. 17, 2014 | In Use | |
00597-0145-60 | 00597-0145 | Nintedanib | Ofev | 150.0 mg/1, 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, FLT3 | Oral | Oct. 17, 2014 | In Use | |
24979-0715-04 | 24979-0715 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF | Oral | Dec. 1, 2022 | In Use | |
24979-0715-44 | 24979-0715 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF | Oral | Dec. 1, 2022 | In Use | |
63629-2067-01 | 63629-2067 | IMATINIB MESYLATE | IMATINIB MESYLATE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb. 8, 2019 | March 31, 2023 | No Longer Used |
68001-0480-22 | 68001-0480 | Irinotecan hydrochloide | Irinotecan hydrochloide | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec. 14, 2020 | In Use | |
68001-0480-35 | 68001-0480 | Irinotecan hydrochloide | Irinotecan hydrochloide | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec. 14, 2020 | In Use | |
68083-0381-01 | 68083-0381 | Irinotecan hydrochloide | Irinotecan hydrochloide | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Nov. 18, 2019 | In Use | |
70700-0169-22 | 70700-0169 | Irinotecan hydrochloide | Irinotecan hydrochloide | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Nov. 18, 2019 | In Use | |
72485-0213-15 | 72485-0213 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Sept. 4, 2020 | In Use | |
68083-0382-01 | 68083-0382 | Irinotecan hydrochloride | Irinotecan hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Nov. 18, 2019 | In Use | |
70700-0170-22 | 70700-0170 | Irinotecan hydrochloride | Irinotecan hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Nov. 18, 2019 | In Use | |
00007-4201-01 | 00007-4201 | Topotecan Hydrochloride | Hycamtin | 4.0 mg/4mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | June 7, 1996 | July 31, 2018 | No Longer Used |
00007-4205-11 | 00007-4205 | Topotecan Hydrochloride | Hycamtin | 0.25 mg/1 | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Oral | Sept. 16, 2008 | Dec. 31, 2017 | No Longer Used |
00007-4207-11 | 00007-4207 | Topotecan Hydrochloride | Hycamtin | 1.0 mg/1 | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Oral | Sept. 16, 2008 | Jan. 31, 2018 | No Longer Used |
00069-0075-01 | 00069-0075 | Topotecan Hydrochloride | Topotecan Hydrochloride | 4.0 mg/4mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Aug. 29, 2012 | Dec. 31, 2016 | No Longer Used |
00009-1111-01 | 00009-1111 | Irinotecan Hydrochloride | Camptosar | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | June 14, 1996 | Oct. 31, 2017 | In Use |
00009-1111-02 | 00009-1111 | Irinotecan Hydrochloride | Camptosar | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | June 14, 1996 | In Use | |
00009-7529-03 | 00009-7529 | Irinotecan Hydrochloride | Camptosar | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | June 14, 1996 | In Use | |
00009-7529-04 | 00009-7529 | Irinotecan Hydrochloride | Camptosar | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | June 14, 1996 | In Use | |
00009-7529-05 | 00009-7529 | Irinotecan Hydrochloride | Camptosar | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | June 14, 1996 | In Use | |
00143-9583-01 | 00143-9583 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec. 20, 2010 | In Use | |
00078-0672-01 | 00078-0672 | Topotecan Hydrochloride | Hycamtin | 0.25 mg/1 | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Oral | July 7, 2017 | In Use | |
00078-0673-01 | 00078-0673 | Topotecan Hydrochloride | Hycamtin | 1.0 mg/1 | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Oral | Feb. 24, 2017 | In Use | |
00078-0674-61 | 00078-0674 | Topotecan Hydrochloride | Hycamtin | 4.0 mg/4mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec. 21, 2016 | In Use | |
00143-9701-01 | 00143-9701 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec. 20, 2010 | In Use | |
00143-9702-01 | 00143-9702 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec. 20, 2010 | In Use | |
00703-4432-11 | 00703-4432 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 40.0 mg/2mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Feb. 28, 2008 | Nov. 30, 2019 | No Longer Used |
00703-4432-81 | 00703-4432 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 40.0 mg/2mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | July 1, 2015 | July 31, 2019 | No Longer Used |
Found 10,000 results in 3 milliseconds — Export these results